MiRus

1.1 Identity, stage, and business model

MiRus presents itself as a medical-technology company building proprietary biomaterials, implants, procedural solutions, and monitoring capabilities for cardiovascular and orthopedic disease. The company website, about page, and technology materials all center the MoRe alloy platform—MiRus' molybdenum-rhenium material base—as the common technical thread across spine, extremity, and structural-heart products. The public contact footprint places the company in Marietta, Georgia, while Boston Scientific's May 2026 investment announcement refers to MiRus' Atlanta-based team; for diligence purposes the supportable conclusion is that MiRus is a metro-Atlanta company with operating addresses in Marietta. The business is clearly beyond concept stage in orthopedics because the company has multiple FDA-cleared spine and extremity products, manufacturing space, a commercial organization, and open operations roles. At the same time, its structural-heart program remains investigational: the SIEGEL balloon-expandable TAVR system is in a pivotal trial and is not approved for commercial distribution in any country. That mix makes MiRus a hybrid company—commercial in spine/orthopedics, clinical-stage in TAVR, and newly recapitalized by a strategic investor around the structural-heart upside.[CO001, CO002, CO003, CO005, CO006, CO021]

1.2 Leadership and operator profile

Official MiRus leadership pages identify Jay Yadav, MD as founder and CEO, not Tom Eichmann. That discrepancy matters because the founder-led story is central to MiRus' public narrative. Yadav is an interventional cardiologist whose prior exits include CardioMEMS to St. Jude/Abbott and Angioguard to Johnson & Johnson; MiRus also credits him as first investor and director of SMART Therapeutics, later acquired by Boston Scientific. The rest of the disclosed operating bench is meaningful for a private company of MiRus' size: Noah Roth is COO and is tied to MoRe alloy development, Mahesh Krishnan leads commercialization, David Toney has been CFO since 2022, Jordan Bauman runs quality and regulatory affairs with experience in 510(k), IDE, and PMA pathways, and Pam Cowart brings long cardiovascular clinical-affairs experience from CardioMEMS. The public team pages therefore show founder-market fit in cardiovascular devices plus a practical bench for orthopedic commercialization and heart-valve trial execution. The key-person caveat is that much of MiRus' external credibility still runs through Yadav personally, including the company origin story, investor messaging, prior-exit halo, and structural-heart vision.[CO004, CO016, CO017, CO018, CO019, CO020]

1.3 Capital structure and strategic transaction

The defining company-overview fact is Boston Scientific's May 18, 2026 strategic investment. Boston Scientific disclosed a $1.5 billion investment for approximately 34% equity in MiRus, which implies an equity value a little above $4.4 billion. The agreement is not a plain minority growth round: Boston Scientific also received an exclusive option to acquire the MiRus TAVR business for additional aggregate cash payments totaling $3 billion after specified clinical and regulatory milestones, plus a further option on mitral and tricuspid valve assets. This structure is simultaneously validating and cautionary. It validates MiRus because one of the world's largest cardiovascular strategics committed very large capital before approval. It is cautionary because the headline enterprise narrative still depends on milestones that have not yet been achieved, and Boston Scientific's full-control outcome is optional rather than committed today. Third-party coverage from Fierce Biotech, MedTech Dive, Nasdaq, and Quartz aligns on the basic economics and reinforces that the heart-valve program is the value driver behind the financing event.[CO007, CO008, CO009, CO010, CO011, CO012]

1.4 Milestones, product proof, and disclosure gaps

MiRus' public milestone trail is now coherent enough to support a chronology. Founder materials published in 2021 described expanded Marietta manufacturing capacity, more than 100 patents, and decades of background work on the alloy platform. Orthopedic commercialization is evidenced by repeated FDA 510(k) clearances, including the 3DR lateral lumbar interbody fusion system with integrated plate fixation in 2023 and multiple earlier EUROPA, IO, and CYGNUS-family devices in the openFDA record. Structural-heart milestones accelerated later: first-in-human SIEGEL data were presented in June 2024, U.S. early-feasibility cases were reported in March 2025, 30-day EFS results were highlighted later in 2025, unconditional FDA approval for the STAR pivotal trial was announced in early 2026, and Boston Scientific's investment landed in May 2026. The missing metrics are still substantial. Public sources do not disclose revenue, customer count, headcount, cumulative historical financing before the Boston Scientific deal, or a clean split between orthopedic revenue and TAVR burn. MiRus is therefore no longer a hidden company, but it is still only partially disclosed as an operating business.[CO021, CO022, CO024, CO025, CO026, CO027]

1.5 Exhibits

2.1 Market Boundary and Scope

MiRus competes in two adjoining segments that share a material-science foundation but have distinct regulatory, reimbursement, and buyer architectures. The structural heart segment encompasses all transcatheter and surgical aortic valve replacement (TAVR and SAVR) procedures, associated delivery and imaging systems, and structural-heart service-line infrastructure at qualified hospitals. Excluded from this boundary are coronary-artery devices, cardiac rhythm management, mitral and tricuspid interventions (though MiRus has an option for those via the Boston Scientific agreement), and non-cardiac vascular procedures. The orthopedic and spine segment encompasses fusion implants (interbody cages, pedicle screws, rods), motion-preserving devices, extremity implants, and adjacent procedural tools where MiRus holds FDA 510(k) clearances. Excluded are large-joint arthroplasty (hip, knee), sports medicine, orthobiologics, and robotics-assisted surgery platforms that MiRus does not currently sell. The status-quo substitutes differ sharply by segment: for structural heart, surgical aortic valve replacement (SAVR) and watchful waiting remain the clinical default for many patient populations; for spine, non-operative management (physical therapy, steroid injections) and existing metal-alloy cages from incumbents are the base case. The common thread is that MiRus's MoRe molybdenum-rhenium alloy replaces conventional materials (cobalt-chromium, nitinol, titanium) in both product families, which is the key differentiation claim but also a hurdle given surgeon familiarity with incumbent alloys. Adjacent spend areas include structural heart imaging (echo, CT), robotic spine navigation, and post-TAVR monitoring, none of which MiRus currently addresses but which influence overall hospital budget allocation and capital committee decisions.[CM001, CM002, CM003, CM007, CM008, CM028]

2.2 Market Sizing — Multiple Lenses

No single authoritative source provides a simultaneously reliable structural heart and spine market size for MiRus's specific addressable population, so the analysis uses multiple lenses that must be reconciled rather than averaged. For structural heart, Grand View Research estimated the global TAVR market at USD 6.8 billion in 2024, projecting 6.6% CAGR to approximately USD 9.9 billion by 2030. North America accounts for roughly 50% or more of global TAVR revenue based on procedure-volume concentration data, implying a US-Canada addressable of roughly USD 3.4 to 4.5 billion. This estimate is materially uncertain because no public source provides a reliable standalone US TAVR revenue figure independent of combined structural heart program reporting. A second lens uses procedure volume: with approximately 90,000 to 130,000 annual US TAVR procedures (range based on TVT Registry and academic reports through 2023) and mean device cost of roughly USD 30,000 to 35,000, a bottom-up estimate yields USD 2.7 billion to USD 4.6 billion, broadly consistent with the GVR top-down figure. For spinal implants, Grand View Research estimated the global market at USD 13.9 billion in 2024, growing to USD 23.1 billion by 2033 at 6.0% CAGR; North America represented 47.8% of this total, implying approximately USD 6.6 billion in 2024 for the US-Canada segment. MiRus currently lacks publicly disclosed revenue for its spine portfolio, preventing calculation of current market share. Conflicting estimates persist: multiple analyst reports—including projections from iData Research, Emergen Research, and Grand View Research—use different base years, procedure definitions, and geographies, generating spread of USD 11.8 billion to USD 14.3 billion for the 2024 global spine market and CAGR ranges of 5% to 6.1% through 2032-2033. Both figures should be treated as order-of-magnitude anchors, not investment-grade inputs, for the MiRus diligence.[CM004, CM005, CM006, CM009, CM027, CM030]

2.3 Buyer, User, and Payer Segmentation

The TAVR buyer and payer landscape is highly institutionalized and concentrated. The primary buyer in structural heart is the hospital capital committee or structural heart service-line administrator, who evaluates system cost, implant pricing, training requirements, and institutional credentialing. The user is the multidisciplinary heart team—typically an interventional cardiologist and a cardiac surgeon acting jointly under AATS/ACC/SCAI/STS consensus requirements—and the payer for the overwhelming majority of procedures is Medicare, which covers TAVR under a National Coverage Determination (NCD) with Coverage with Evidence Development (CED) conditions. Approximately 88% of TAVR procedures are performed in hospitals according to Grand View Research end-use data, with the remainder at ambulatory surgical settings, though complex structural heart cases are almost exclusively at hospital-based programs. For the SIEGEL valve specifically, payer access is currently constrained to CMS-approved CED clinical-study enrollment; commercial reimbursement is not available until FDA approval. The spine buyer map differs meaningfully: the budget owner is typically the orthopedic or spine surgery department head and the hospital supply chain committee, with surgeons exercising significant choice through consignment-style implant programs. The payer mix is broader and more commercially varied—Medicare, Medicaid, commercial insurers, and workers' compensation all feature—though Medicare still covers the majority of spinal fusion in patients over 65. Adoption triggers in spine favor surgeons with prior positive material experience, which is why MiRus building clinical data and key-opinion-leader support through its 510(k)-cleared portfolio matters for commercial momentum. A third category—ambulatory surgery centers (ASCs) for less complex spine procedures—represents a growing segment where novel implant materials may see faster uptake due to fewer capital-committee gatekeepers, but MiRus has not publicly identified ASC penetration as a current focus.[CM010, CM011, CM012, CM015, CM016, CM017]

2.4 Growth Drivers

Several reinforcing factors support above-market-average growth in the TAVR segment over the next decade. First, demographic expansion: the WHO projects the global population aged 60 and older will double to 2.1 billion by 2050, and calcific AS prevalence is 1,841 cases per 100,000 adults aged 70 and older globally—approximately 12.6 million people today. In the US alone, AS affects 5% of adults 65 and older (roughly 2.1 million people) according to CDC data. Second, indication expansion: the FDA approved the Edwards SAPIEN 3 platform for asymptomatic severe AS in May 2025, the first-ever approval for this population. CMS is now reconsidering its NCD to cover asymptomatic TAVR following Edwards's formal request citing the EARLY TAVR randomized trial, in which the composite endpoint (death, stroke, unplanned hospitalization) occurred in 26.8% of TAVR patients versus 45.3% under watchful waiting. Extending TAVR to asymptomatic patients could meaningfully expand the addressable procedure volume, though payer acceptance remains contested as many cardiologists oppose asymptomatic treatment. Third, age-group penetration: TAVR has shifted from a high-risk-only procedure to the dominant modality in patients 65 and older. In the 65–80 age group, TAVR utilization doubled from 42.1% to 80.6% of AVR procedures between 2016 and 2022; in the over-80 group it reached 97.8%; and even in the under-65 group—historically SAVR territory—TAVR reached 51.7% of procedures by 2022. For spine, growth drivers include an aging population with rising degenerative disc disease burden, expansion of minimally invasive surgical techniques, and MiRus's proprietary MoRe alloy, which may reduce imaging artifact and improve bone integration compared to titanium or cobalt-chromium implants, though independent comparative outcome data at scale are not yet publicly available.[CM003, CM007, CM008, CM009, CM013, CM014]

2.5 Adoption Constraints, Reimbursement, and Diligence Gaps

Multiple structural constraints limit adoption speed for TAVR entrants, independent of clinical merit. Institutional credentialing requirements jointly established by AATS, ACC, SCAI, and STS require a full structural heart program with on-site cardiac surgery, a cardiac catheterization laboratory, CT imaging, a multidisciplinary heart team, and documented procedural volume before a hospital can offer TAVR commercially. These requirements effectively limit the commercial market to hospitals that have already committed substantial capital and achieved adequate case volume, concentrating TAVR revenue at roughly 700–900 high-volume centers in the US. For MiRus, the STAR pivotal trial's enrollment at CMS-approved CED sites provides access only to that small set of investigational sites during the pre-approval period; every new SIEGEL center requires credentialing infrastructure that MiRus cannot bypass. Reimbursement timing is a second constraint: even after FDA approval, CMS coverage determinations for new TAVR devices can take 12–24 months, creating a window where FDA-approved but not-yet-reimbursed procedures generate hospital cost exposure. Surgeon training and proctoring requirements impose additional adoption friction; new TAVR platforms typically require 10–20 supervised cases before independent implantation certification, multiplying per-center launch cost and time. Capital intensity at the hospital level—hybrid OR suites, CT infrastructure, echo lab, perfusion standby—anchors TAVR programs at well-capitalized centers and slows expansion to community settings. Incumbent market concentration is the most durable constraint: Edwards Lifesciences and Medtronic together control the large majority of TAVR procedures globally through SAPIEN and Evolut product lines, while Abbott holds a smaller but growing share with Navitor. Boston Scientific's own prior attempt to build a market position with the ACURATE Neo2/Prime platform in Europe while seeking US approval ultimately resulted in product discontinuation, demonstrating that technical merit alone does not guarantee share capture even for a well-capitalized sponsor. In orthopedic spine, switching costs are lower than TAVR given the consignment-style implant logistics, but DePuy Synthes, Stryker, and Zimmer Biomet have deeply embedded sales and clinical support networks. Key diligence gaps include the absence of public MiRus spine revenue and market share, lack of SIEGEL clinical outcome data beyond 30-day EFS follow-up, and unresolved CMS asymptomatic TAVR coverage determination that would substantially affect the addressable procedure pool.[CM011, CM015, CM016, CM025, CM026, CM036]

2.6 Exhibits

3.1 TAVR Competitive Landscape — Direct Peers and Structural Dynamics

The US TAVR market is effectively a duopoly. Edwards Lifesciences controls approximately 60–70% of US TAVR procedures through its balloon-expandable SAPIEN 3 and SAPIEN 3 Ultra platforms. Edwards' full-year 2025 TAVR revenue reached $4.5 billion, a year-over-year increase of 8.6%, demonstrating that the incumbent remains in a strong growth trajectory rather than a maturing plateau. Medtronic captures the remaining ~30–35% with its self-expanding Evolut FX platform. The two-year SMART trial data, which compared Evolut to SAPIEN in patients with small aortic annuli and predominantly female enrollment, showed Evolut with significantly less bioprosthetic valve dysfunction, five times less prosthetic valve thrombosis, and nine times less haemodynamic structural valve dysfunction — findings that may incrementally shift physician preferences in this patient subset but have not yet displaced Edwards' overall dominance. Abbott holds a small but expanding position with the Navitor system (FDA-approved January 2023 for high-risk patients), reporting 0% moderate-to-severe PVL, a mean gradient of 7.4 mmHg, and all-cause mortality of 1.9% in approval data. The ENVISION trial is broadening Navitor's label. Cardiologist surveys in 2024 predicted Edwards' US share would settle near 72% by 2025 as Abbott ramps, but the data still makes TAVR a two-horse race for total volume. Boston Scientific is no longer a TAVR competitor. After years of pursuing FDA approval for Acurate neo2, BSX discontinued all Acurate commercial, clinical, and manufacturing activity in May 2025. The Acurate IDE trial, reported at TCT 2024 and published in The Lancet, showed Acurate neo2 failed to meet the prespecified 8% noninferiority margin against both Evolut and SAPIEN; approximately 20% of valves were under-expanded, which contributed to worse one-year outcomes. BSX had $200 million in Acurate sales in 2024 before discontinuation. The exit is strategically significant for MiRus: BSX's May 2026 $1.5 billion investment and $3 billion call option on the SIEGEL business reflect a clear acknowledgment that BSX cannot independently rebuild TAVR capability and sees MiRus as its re-entry vehicle. This dual role — strategic partner today, option holder tomorrow — means BSX is simultaneously validating MiRus and retaining the optionality to control or internalize the SIEGEL asset. Anteris Technologies is the most directly relevant new entrant. Its DurAVR balloon-expandable THV received FDA IDE approval in November 2025 for the PARADIGM pivotal trial (NCT07194265), which will randomize ~1,000 patients at 1:1 against commercial TAVR (SAPIEN/Evolut) across the US, Europe, and Canada. DurAVR uses a biomimetic single-piece ADAPT tissue design. PARADIGM and the MiRus STAR trial are running in parallel, meaning two pre-approval entrants are competing for investigational site access and enrollment simultaneously. JenaValve and JC Medical are also in FDA trials for aortic regurgitation indications; both were acquired by Edwards in 2024, pending FTC review of JenaValve, further concentrating Edwards' pipeline hold. The status quo substitute for TAVR remains surgical aortic valve replacement (SAVR), which retains guideline preference for patients under 65. SAVR is performed by cardiac surgeons at the same institutions and holds long-term durability data that no TAVR system can yet match. Non-operative watchful waiting is the default for asymptomatic patients, though the May 2025 FDA approval of SAPIEN for asymptomatic severe AS (based on EARLY TAVR data) is beginning to erode that default.[CP001, CP002, CP003, CP004, CP005, CP006]

3.2 Orthopedic and Spine Competitive Landscape

In spinal implants and devices, MiRus faces a concentrated market where three companies command the majority of global revenue. Medtronic holds the leading position across most major spine segments in 2024, including cervical fixation, thoracolumbar fixation, and interbody devices, supported by a broad portfolio spanning traditional fusion and motion preservation. DePuy Synthes (Johnson & Johnson) is the second-largest global spine competitor, with 2025 combined spine, sports, and other revenue of $2.8 billion (down 2.5% year-over-year), holding strong positions in interbody devices, cervical fixation, and thoracolumbar fixation. Johnson & Johnson has announced strategic work to evaluate DePuy Synthes as a standalone orthopedic entity, which could reshape competitive dynamics and lead to different investment priorities. Stryker is undergoing a significant structural shift: after reporting only $185 million in spine revenue for full-year 2025, the company agreed in January 2025 to divest its US and France spinal implant business to Viscogliosi Brothers (VB Spine). Stryker is repositioning around enabling technology platforms including robotic navigation (Q Guidance System) and Balance ACS planning software, rather than commodity implants. This creates a partial competitive opening in implant categories but simultaneously raises the robotics and navigation bar that small implant players like MiRus must integrate with. Zimmer Biomet reported total 2025 sales of $8.2 billion and has not announced a spine divestiture, maintaining its position as a full-line orthopedic competitor with a strong knee and hip core. Its spine and extremity exposure is embedded in broader platforms and distributed through a large direct sales force. The global spinal implant and vertebral compression fracture (VCF) market reached $21.4 billion in 2024 and is projected to grow to approximately $32 billion, per iData Research. Key growth drivers include minimally invasive surgery (MIS) workflow adoption, ASC migration, and robotics integration — all areas where incumbents are investing while MiRus competes on material science differentiation alone. Titanium and PEEK remain the dominant implant materials; proprietary alloys face a skeptical market conditioned by decades of competitor data. MiRus holds 24 FDA 510(k) clearances for spine and extremity implants, providing a commercial foothold, but publicly disclosed revenue and market share for its spine business are unavailable, making competitive position impossible to quantify from public sources. The relevant substitutes in spine are non-operative management (physical therapy, injections, bracing), existing titanium or PEEK implants from established vendors, and increasingly, biologic augmentation. The switching cost from a current spine surgeon's preferred vendor is high: proctoring, tray costs, OR familiarity, and field rep relationships all favor incumbents.[CP014, CP015, CP016, CP017, CP018, CP019]

3.3 Capability Comparison and Differentiation Analysis

In TAVR, MiRus differentiates SIEGEL through three primary technical claims: an 8-French transfemoral access sheath (the company describes this as smaller than competing platforms), a nickel-free and cobalt-free rhenium alloy frame that the company argues reduces hypersensitivity risk and improves fatigue performance, and the absence of foreshortening during deployment that the company claims enables more precise positioning. SAPIEN 3 uses a cobalt-chromium frame delivered via a 14-French equivalent Commander delivery system. Evolut FX uses a nitinol (nickel-titanium) self-expanding frame via a 14-French InLine sheath. Abbott Navitor describes its FlexNav delivery system as having the largest valve in the smallest delivery system at that size range. On measured hemodynamic performance, the SIEGEL 30-day EFS data (15 patients, five US centers) showed a mean gradient of 6.3 mmHg and valve area of 2.8 cm². By comparison, Navitor's approval data reported a mean gradient of 7.4 mmHg and EOA of 2.0 cm². These comparisons are not head-to-head and involve different populations, different follow-up windows, and different imaging protocols; they should not be treated as evidence of superiority. SIEGEL's clinical dataset is 15 patients at 30 days; SAPIEN 3 and Evolut FX are supported by years of post-market data from registries containing hundreds of thousands of procedures. The asymmetry in evidence depth is the most important near-term competitive disadvantage for MiRus. In spine, SIEGEL's alloy differentiation is replicated by the MoRe alloy across the orthopedic platform. Titanium-alloy and PEEK interbody cages from Medtronic, DePuy, and Stryker dominate because surgeons, hospitals, and payers have decades of outcome data. MiRus's MoRe alloy claims high yield strength, fatigue resistance, and MRI compatibility improvements, but published long-term comparative outcomes data in spine remains limited. This creates a credibility gap that must be closed with surgeon-level clinical adoption and independent published data. For pricing and packaging, TAVR device pricing at US hospital centers is not publicly disclosed by any manufacturer. Market reports estimate TAVR system costs at approximately $30,000–$35,000 per procedure; this is consistent with a bottom-up US market size estimate of $2.7–$4.6 billion at 90,000–130,000 annual procedures. MiRus pricing is entirely unknown since SIEGEL is currently an investigational device with no commercial price list. Spine implant pricing from incumbents is similarly negotiated bilaterally and not publicly disclosed; MiRus does not disclose list prices for its commercial spine portfolio.[CP020, CP021, CP022, CP023, CP026, CP035]

3.4 Distribution, Switching Costs, and Lock-In

TAVR operator and institutional relationships are the primary moat protecting Edwards and Medtronic. Multi-society credentialing requirements (AATS/ACC/SCAI/STS) mandate that TAVR programs maintain specific procedural volumes and operator training standards; programs that have built training infrastructure around one platform's proctoring, simulators, and field support face material switching costs. Edwards operates the Edwards Learning Network providing structured training, case support, and online modules; Medtronic offers equivalent training infrastructure. Both companies also provide comprehensive reimbursement support desks, CT planning tools, and dedicated structural heart service-line resources — infrastructure that MiRus cannot match at its current scale. Hospital capital committee decisions integrate device approval into multi-year service-line contracts that often include bundled pricing across a company's larger portfolio. For a health system that relies on Medtronic for CRM, neuromodulation, and spine navigation, resisting Medtronic's TAVR bundling pressure is difficult. The same applies to Edwards, whose structural heart program extends into mitral and tricuspid territory. These cross-portfolio relationships create soft-dollar switching costs invisible to any per-device price comparison. For spine, the OR relationship is centered on the field sales representative who manages trays, provides intraoperative guidance, and maintains surgeon preferences. Changing implant vendors requires training, tray restocking (a material hidden cost), and rebuilding OR staff familiarity. ASC migration is shifting some purchasing toward cost-first procurement, which could partially benefit a differentiated material science entrant like MiRus that can compete on total implant-level value, but the rep-driven model still dominates hospital spine procurement. Multi-homing — using both SAPIEN and Evolut depending on anatomy — is already common practice at high-volume TAVR centers. Most large programs maintain access to both platforms. This suggests that a center can add SIEGEL without abandoning incumbents, which is favorable for MiRus adoption post-approval. However, it also means centers have little urgency to exclusively commit to SIEGEL, limiting MiRus's ability to command preferred vendor status in the near term.[CP024, CP025, CP028, CP037]

3.5 Moat Durability and Displacement Risk

The adverse evidence pattern in TAVR is stark. Boston Scientific's full TAVR exit — after acquiring Symetis for $435 million in 2017 and spending years pursuing FDA approval for both Lotus Edge (discontinued 2020) and Acurate neo2 (discontinued 2025) — is the clearest available signal of how hard it is to displace Edwards and Medtronic. BSX is one of the world's largest medtech companies by revenue and failed at TAVR twice. The Acurate IDE trial failure, where approximately 21.6% of valves were under-expanded due to operator inexperience at less experienced centers, illustrates that procedural complexity and training investment are not easily transferred. MiRus SIEGEL's 8-French low-profile design may mitigate some deployment complexity, but the principle stands: TAVR adoption for new systems is structurally gated by operator trust, institutional credentialing, and comparative outcomes data that only accumulate over years. Medtronic continues to invest in its platform. The Evolut FX+ is an incremental advance with updated deployment features. The SMART trial five-year results are still pending and may further support Medtronic's differentiation in the small-annulus patient segment. Edwards' 7-year PARTNER 3 data and its acquisition of JenaValve and JC Medical position it to expand into aortic regurgitation — adjacent indications where MiRus does not yet have data. These incumbent innovation vectors mean the competitive gap does not stand still. For MiRus, the $3 billion BSX call option is simultaneously the most validating and most threatening structural feature. If BSX exercises the option, MiRus TAVR ceases to be an independent business — its distribution, commercialization, and strategic direction pass to a large incumbent. This is not inherently adverse (BSX has superior commercial reach), but it changes the risk profile for investors betting on MiRus as an independent structural heart company. If BSX declines the option, MiRus must build its own TAVR commercial infrastructure from scratch — field hiring, hospital contracting, training programs, reimbursement support — against two entrenched competitors with decades of institutional relationships. In spine, moat durability for MiRus depends on its ability to generate surgeon-level outcomes data that justifies the unfamiliar alloy and builds clinical trust over time. Stryker's implant divestiture and JnJ's potential DePuy spinoff create organizational disruption among the top three, but disruption does not automatically benefit a small player. The winners from large competitor reorganizations are typically well-funded mid-tier companies with established sales forces — not early-stage entrants with limited public clinical evidence.[CP006, CP007, CP029, CP036, CP009, CP030]

3.6 Exhibits

4.1 Revenue model and business-unit structure

MiRus operates two structurally distinct revenue models that coexist under a single holding entity. The first is a conventional medical-device commercial operation in spine and orthopedics: MiRus sells FDA-cleared hardware implants and procedural instruments to hospitals and ambulatory surgery centers through a distributor network. The product portfolio confirmed by public sources includes at least 24 510(k)-cleared devices across cervical spine (EUROPA PCF, RIGEL, CYGNUS systems), lumbar spine (IO Expandable Lumbar Interbody, ANTARES, 3DR LLIF), extremity (IO Expandable Wedge Osteotomy), and procedural solutions (GALILEO, VITESSE). The commercial mechanics are standard for premium spine: MiRus ships consigned instrument trays, generates per-procedure revenue on implant sales, and differentiates on the MoRe alloy's mechanical properties and, more recently, on NTAP reimbursement support from CMS for the EUROPA PCF system. The NTAP designation, effective 2024–2025, entitles qualifying Medicare inpatient cases to incremental reimbursement, which lowers the economic friction for hospital adoption but does not itself constitute a direct MiRus revenue line. The second business is pre-commercial: the SIEGEL TAVR system is an investigational device in the STAR pivotal trial. No TAVR revenue exists today; the relevant financial metric for this track is clinical trial burn and regulatory spend rather than sales. Boston Scientific's May 2026 investment and option structure are the primary financing vehicle for the TAVR track. The two tracks share the MoRe alloy platform and manufacturing infrastructure, which creates some operating leverage, but their revenue timing, risk profiles, and capital requirements differ materially.[CI001, CI002, CI003, CI004, CI005, CI006]

4.2 Boston Scientific transaction economics and option structure

The May 18, 2026 Boston Scientific transaction is the most consequential financial event in MiRus' history and deserves its own analytical treatment. Boston Scientific paid $1.5 billion for approximately 34% equity in MiRus, implying a pre-money equity value of roughly $2.9 billion and a post-money equity value of approximately $4.4 billion. That implied valuation is not independently audited or verified outside of the BSX announcement; it is arithmetic derived from the disclosed equity fraction and the investment quantum. The agreement also granted Boston Scientific an exclusive option to acquire the MiRus TAVR business for additional aggregate cash payments totaling $3 billion, contingent on the completion of certain clinical and regulatory milestones. A further option covers MiRus mitral and tricuspid valve assets at unspecified terms. These structures deserve careful financial interpretation. The $3 billion option is not a committed obligation; Boston Scientific retains the right, but not the obligation, to exercise it. The milestone triggers are not publicly disclosed in detail. From MiRus' perspective, the option is a validation mechanism and a financing backstop — if SIEGEL succeeds in the STAR trial and receives FDA approval, BSX can acquire the TAVR business for what would be a total consideration of $4.5 billion ($1.5B investment plus $3.0B option exercise), representing a substantial multiple on the implied post-money equity for the TAVR business alone. The $1.5 billion investment itself provides significant near-term capital: even assuming the orthopedic business has meaningful but undisclosed operating burn, the infusion is large enough to fund the STAR trial through enrollment and readout, based on comparable pivotal TAVR trial cost structures documented in public comparators. Boston Scientific's 2025 annual revenue was $20.07 billion with its cardiovascular segment growing approximately 18%, and the company explicitly cited a strategic need to re-enter the TAVR market following its Acurate platform withdrawal. The investment therefore reflects strategic optionality for BSX as much as capital supply for MiRus.[CI009, CI010, CI011, CI012, CI013, CI014]

4.3 Unit economics, pricing benchmarks, and margin proxies

MiRus does not publicly disclose ASP, gross margin, or unit-level economics for its spine/orthopedic portfolio. Benchmarks from comparable spine and TAVR medtech companies provide the only public reference frame. For spine implants, the competitive landscape suggests per-procedure hardware ASPs of approximately $3,000–$15,000 depending on system complexity, with cervical and lumbar interbody fusion devices typically in the $5,000–$12,000 range. Top-tier spine manufacturers (Stryker, J&J DePuy Synthes, Zimmer Biomet) operate at gross margins of approximately 60–70% of product revenue; premium-material, higher-differentiation portfolios like MiRus' MoRe alloy systems could in principle command premium pricing if the clinical case for durability reduction in revision procedures gains hospital acceptance, but the realized ASP is a private-data gap. For TAVR, publicly reported reference points are more specific: Edwards Lifesciences' SAPIEN platform and Medtronic's Evolut system sell at approximately $25,000–$35,000 per valve, consistent with Edwards' FY2025 TAVR revenue of $4.5 billion across an estimated 150,000–200,000 annual procedures globally. CMS DRG reimbursement for an inpatient TAVR case (MS-DRG 266–267) typically ranges from $45,000–$60,000 per case, making the device cost the largest single component of the hospital episode. MiRus would price SIEGEL within or slightly above this range to be commercially viable; any premium over SAPIEN/Evolut ASP would need to be justified on clinical or access grounds. The 8-Fr delivery profile and nickel-free design position SIEGEL for premium pricing in specific patient segments (women, nickel-allergic patients) but whether payers will reimburse above the existing DRG without a new technology add-on payment path for TAVR (analogous to the NTAP awarded for EUROPA in spine) remains an open question.[CI018, CI019, CI020, CI021, CI022, CI023]

4.4 Capital adequacy, burn rate, and financing dependency

The $1.5 billion BSX investment represents the largest single disclosed financing event in MiRus' history. Public sources do not disclose prior cumulative fundraising, exact cash on hand, or current monthly burn rate; the Company Overview chapter documents the funding chronology through the BSX deal from public sources without specifying pre-2026 fundraising amounts. From a capital adequacy standpoint, the relevant analysis is whether the $1.5 billion investment is sufficient to fund MiRus through the STAR trial to readout and potential PMA submission. STAR is enrolling 1,025 patients at multiple U.S. centers; the primary endpoint is a composite of mortality, stroke, and cardiovascular hospitalization at 1 year. Based on publicly documented costs for comparable pivotal TAVR trials, a 1,000-patient randomized controlled trial from enrollment to 1-year primary endpoint readout typically costs $100–$250 million in clinical operations alone, with regulatory affairs, quality, manufacturing scale-up, and general and administrative expenses adding further. The MiRus orthopedic commercial operation also requires ongoing sales-force, distributor, and inventory support. Even with conservative assumptions, the $1.5 billion investment provides substantial runway — likely well beyond the 1-year STAR primary endpoint, with capacity for a potential PMA or 510(k) pathway submission and early commercial planning. The primary financing dependency is therefore not on additional near-term capital but on the milestone-conditional $3 billion BSX option: if STAR fails or is materially delayed, the option would likely not be exercised, and MiRus would face a recapitalization event for its TAVR program. The orthopedic commercial business provides a revenue-generating offset to TAVR burn, but scale is undisclosed. No credit facilities, project finance arrangements, or inventory-backed lending programs are publicly described.[CI026, CI027, CI028, CI029, CI030, CI031]

4.5 Public traction proxies and missing private metrics

MiRus is a private company with limited voluntary financial disclosure. The publicly accessible traction signals are almost exclusively clinical and regulatory rather than commercial or financial. For the orthopedic business, observable proxies include: 24 510(k) clearances confirming a productized commercial portfolio; an NTAP designation for EUROPA PCF confirming CMS recognized the system as sufficiently novel for incremental Medicare reimbursement; Breakthrough Device Designation for EUROPA PCF; open sales and commercial operations roles in public job postings; and distributor-channel references in public press releases. None of these translates directly into revenue, units, or gross profit. For TAVR, the most meaningful traction signals are clinical: 15 EFS patients with zero 30-day major adverse events, enrollment in the 1,025-patient STAR pivotal trial, and the BSX investment itself as a form of strategic validation. Boston Scientific invested $1.5 billion after reviewing MiRus' non-public data room, making its decision a high-quality signal about the quality of the underlying evidence — but it does not substitute for disclosed financials. Material missing metrics include: (1) total company revenue and revenue growth; (2) orthopedic business unit revenue and margin; (3) customer count, distributor count, and procedure volume; (4) TAVR trial site count at STAR enrollment; (5) monthly cash burn; (6) pre-BSX fundraising total; (7) gross margin on spine hardware; (8) realized ASP vs. list ASP for orthopedic products; and (9) inventory carrying value and turns. Any financial model for MiRus that uses assumed revenue or margin figures must be labeled as estimated, not observed.[CI033, CI034, CI035, CI036, CI037, CI038]

4.6 Financial verdict

MiRus' financial profile is determined by two competing realities. The first is strategic validation: a $1.5 billion BSX investment at an implied ~$4.4 billion equity valuation, with a $3 billion option on the TAVR business, is among the largest pre-approval medical device financing events in the TAVR category and provides adequate near-term capital for trial completion. The second is informational opacity: the company discloses no revenue, no margin, no burn rate, and no unit economics. The result is a financial case that cannot be fully underwritten from public data alone. Revenue quality for the orthopedic segment is partially inferable — 24 cleared products, CMS NTAP support, and a functioning distributor channel suggest a real commercial operation — but the scale, growth trajectory, and margin structure are unknown. The TAVR business is entirely pre-revenue: SIEGEL is investigational, STAR is in enrollment, and any TAVR revenue is at minimum 3–5 years away under an optimistic regulatory timeline. The capital adequacy question is largely resolved by the BSX deal: $1.5 billion is more than sufficient to fund STAR enrollment and primary endpoint readout. The underwriting blocker is not capital adequacy per se but option dependency: if STAR does not demonstrate non-inferiority to SAPIEN or Evolut on its 1-year composite endpoint, BSX is not obligated to exercise the $3 billion option, and the standalone enterprise value reverts to the orthopedic business plus any residual pipeline optionality. Margin path analysis remains speculative without a diligence conversation: MoRe alloy differentiation could support premium pricing in both spine and TAVR, but manufacturing scalability, COGS trajectory, and realized vs. list pricing are all private-data gaps. The verdict is that MiRus' financial profile is strategically sound but operationally opaque — sufficient for a high-interest diligence queue but not yet underwritable without private access.[CI039, CI040, CI041, CI042, CI043]

4.7 Exhibits

5.1 MoRe Alloy Platform — Core Material Science

MiRus' entire product and technology strategy rests on MoRe®, a Molybdenum-47.5Rhenium (Mo-Re) binary alloy that the company first developed with inspiration from NASA rocket-engine material science and that the FDA cleared for use in medical implants in 2019. The alloy has been in development for over 15 years. The primary mechanical advantage is a combination of high yield strength, superior fatigue resistance, and minimal recoil compared with the two alloys that currently dominate the spinal implant market — titanium (Ti-6Al-4V) and cobalt chromium (Co-28Cr-6Mo). Critically, an in-vitro corrosion study published in Spine Journal (2023) measured metal ion release from MoRe® in both physiologic and inflammatory saline environments using ICP-MS methods. MoRe® stayed far below the FDA-permitted daily exposure (PDE) limits for molybdenum (1,900 μg/cm² day) and rhenium (4,400 μg/cm² day) throughout all tested intervals, including the inflammatory condition. The same study found that cobalt-chromium approached or exceeded its PDE for cobalt and vanadium under inflammatory conditions — a direct safety contrast. The alloy is nickel-free and cobalt-free. In the structural-heart context, MiRus uses a nitric oxide-coated rhenium frame for the Siegel TAVR, citing radial strength greater than cobalt or titanium. These material properties enable design choices that would be infeasible with legacy alloys: a 2.9 mm posterior cervical rod in EUROPA PCF (versus 3.5–4.0 mm for commercial equivalents), a 3 mm lumbar interbody insertion profile that expands to 16 mm, and an 8 French TAVR delivery system against the industry standard of roughly 14–16 French. The company claims more than 100 patents covering the alloy and derived device designs.[CE001, CE002, CE003, CE004, CE005, CE006]

5.2 Spine and Orthopedic Product Portfolio

MiRus has commercialized a broad, MoRe-enabled spine and orthopedic portfolio across pedicle screw fixation, interbody fusion, anterior cervical hardware, and foot-and-ankle osteotomy. The EUROPA® Pedicle Screw System is the flagship spine fixation product, using MoRe rods and offering a lifetime limited warranty on rod fracture — a warranty that the company frames as a direct signal of mechanical confidence in the alloy. EUROPA® is available in 4.5 mm and 5.5 mm rod diameters for thoracolumbar surgery. The EUROPA® Posterior Cervical Fusion (PCF) system uses a 2.9 mm MoRe rod, which is materially smaller than any comparable commercial system and reduces hardware prominence, particularly in smaller patients. FDA awarded EUROPA® PCF Breakthrough Device Designation in July 2024. FDA 510(k) clearance for EUROPA® PCF was granted under K242516 in November 2024. The IO™ Expandable Lumbar Interbody System expands the expandable platform to the lumbar spine: it enters at a 3 mm insertion profile and expands continuously to 16 mm with 0–23° of lordosis and 2.5 cc graft volume, targeted at patients with degenerative disc disease at L1–S1. The MiRus 3DR™ LLIF system with integrated plate fixation cleared via K232154 in September 2023. Additional products include RIGEL 3DR™ (cervical corpectomy and standalone cervical interbody), ANTARES 3DR™ (standalone ALIF), CYGNUS MoRe® Anterior Cervical Plate, PROMETHEUS Adult Deformity System, and MoRe® Lumbar Plates. In the extremity segment, the IO™ Expandable Wedge Osteotomy System received FDA 510(k) clearance in February 2026 and commercially launched immediately; it applies the same expansion engine to Evans osteotomies for lateral column lengthening in foot and ankle surgery, allowing surgeons to fine-tune bone correction intraoperatively. OpenFDA records show a total of 24 MiRus 510(k) clearances on file as of June 2026.[CE009, CE010, CE011, CE012, CE013, CE014]

5.3 Siegel TAVR — Structural Heart Platform

The SIEGEL™ Transcatheter Aortic Valve (TAVR) is MiRus's structural heart device, a balloon-expandable transcatheter heart valve for the treatment of symptomatic severe aortic stenosis. The device is designed around three interlinked features enabled by the rhenium alloy frame: an 8 French expandable delivery sheath, an open-cell frame that eliminates foreshortening during deployment, and intrinsic commissural alignment. Boston Scientific confirmed in its May 2026 investment announcement that the 8 Fr sheath is approximately 50% smaller than current commercially available TAVR delivery sheaths, which run 14–16 French. All three valve sizes — 23 mm, 26 mm, and 29 mm — are delivered through the same 8 Fr sheath, and the valve arrives pre-mounted on the balloon. The frame is coated with nitric oxide and the leaflets are dry porcine pericardial tissue treated against calcification. Siegel is the only nickel-free THV system on the market per MiRus and Boston Scientific, enabling treatment of patients with nickel allergies (estimated at 20% of Americans according to MiRus). First-in-human results from five patients treated at Instituto Nacional del Torax in Santiago, Chile (June 2024) showed no mortality, stroke, permanent pacemaker, or vascular complications at 30 days; mean gradient was 6.7 mmHg. The U.S. early feasibility study (EFS, NCT06680427) enrolled 15 patients at five centers; 30-day data presented at New York Valves (July 2025) showed no deaths, strokes, rehospitalizations, vascular complications, paravalvular leak, or permanent pacemaker implantations. Core lab echo data showed mean gradient 6.3 mmHg and valve area 2.8 cm². The FDA unconditionally approved the STAR pivotal trial (IDE) in November 2025. STAR is a 1,025-patient prospective multicenter RCT randomizing 1:1 to Siegel or a commercially available balloon- or self-expanding THV; primary endpoint is composite mortality, stroke, and cardiovascular hospitalization at one year. First patients were enrolled at Piedmont Heart Institute on April 8, 2026. The STAR trial is chaired by Martin Leon and Vinod Thourani; national PIs include Pradeep Yadav, Raj Makkar, Samir Kapadia, and Philippe Genereux.[CE019, CE020, CE021, CE022, CE023, CE024]

5.4 Manufacturing, Deployment, and Clinical Workflow

MiRus operates an internal manufacturing base in Marietta, Georgia. The company's 2021 founder profile referenced approximately 70,000 square feet of manufacturing space after a 50,000 sq ft expansion added to an existing 20,000 sq ft facility. Job postings as of 2025–2026 show that MiRus has in-house cardiovascular tissue processors (for the porcine pericardial leaflets in Siegel) and manufacturing associates for orthopedic implants, confirming vertical integration for both product lines. The company also maintains an in-house TAVR clinical research team — including in-house Clinical Research Associates, cardiology nurses, and field clinical specialists — that operationally supports the EFS and STAR trial. For spine and orthopedic products, the commercial model uses a distributor network; MiRus carries a distributor page and EXPECT MoRe® educational series for surgeon training. GALILEO™, MiRus's procedural solutions suite, spans three modules: GALILEO™ Surgical Planning, GALILEO™ Spine Alignment Monitoring System (intraoperative), and GALILEO™ Remote Physiologic Monitoring for post-operative surveillance. The VITESSE™ Pedicle Screw Insertion System rounds out procedural tools for spine. For structural heart, the TAVR clinical workflow requires a dedicated structural heart team (interventional cardiologist and cardiac surgeon), a catheterization lab with fluoroscopic guidance, and appropriate vascular access preparation. EFS data indicate that patients treated with the Siegel 8 Fr system were discharged next day without complications, consistent with the low-access-site-trauma profile that the smaller sheath diameter is designed to achieve. Manufacturing for TAVR tissue valves involves separate tissue-processing operations from metal implant manufacturing; MiRus's in-house tissue processing capability is documented through job postings rather than regulatory filings, and the precise scale is not publicly disclosed.[CE033, CE034, CE035, CE036, CE037]

5.5 Differentiation, IP, and Competitive Positioning

MiRus's primary differentiation thesis across both business segments is the MoRe® alloy platform applied to device designs that cannot be replicated with titanium or cobalt chromium. In structural heart, the 8 Fr delivery system (versus Edwards SAPIEN 3 Ultra and Medtronic Evolut FX, both requiring 14–16 Fr sheaths), the elimination of foreshortening, and the nickel-free construct represent product features that no currently approved TAVR device offers simultaneously. Boston Scientific's May 2026 investment press release explicitly validated these differentiators, noting that the Siegel 'may set it apart from currently available technology.' The $3 billion milestone-based option to acquire the TAVR business — contingent on clinical and regulatory milestones — further implies that a major strategic buyer places high option value on the technology differentiation. In spine, the lifetime limited warranty on MoRe® rod fracture is a direct commercial expression of confidence in the material, since rod fracture is a known complication in adult spinal deformity surgery. The Breakthrough Device Designation for EUROPA® PCF reflects FDA's assessment that the device offers potential substantial improvement over existing alternatives. With more than 100 patents covering the alloy and device designs (company-claimed), the IP moat is potentially broad, though specific patent numbers and expiry dates are not publicly disclosed. On the competitive landscape: J&J DePuy Synthes and Stryker spine use titanium and CoCr systems without proprietary alloy differentiation; Zimmer Biomet similarly relies on conventional alloys. No disclosed competitor is developing a MoRe-equivalent alloy. In TAVR, current commercial competition is Edwards (SAPIEN 3 Ultra, SAPIEN 3 Ultra RESILIA), Medtronic (Evolut FX, Evolut Pro+), and Abbott (Navitor), none of which uses an 8 Fr delivery system or claims nickel-free status.[CE038, CE039, CE040, CE041, CE042, CE043]

5.6 Regulatory, Quality, Safety, and Technical Risks

MiRus's regulatory posture is materially bifurcated: the orthopedic/spine portfolio is commercially deployed under 24 FDA 510(k) clearances (Class II devices), while the SIEGEL TAVR is an investigational device operating under an IDE with no PMA yet filed. The EUROPA® PCF system holds both a 510(k) clearance (K242516, November 2024) and FDA Breakthrough Device Designation — and separately was awarded a New Technology Add-on Payment (NTAP) from CMS, which indicates reimbursement recognition for the novel technology but is time-limited. The in-vitro MoRe® metal ion release study (Spine Journal 2023) establishes a favorable safety profile for short-term physiologic and inflammatory conditions, but long-term in-vivo data in humans are not publicly available. No published clinical outcome studies for MiRus spine products (e.g., fusion rates, revision rates, patient-reported outcomes) have been identified in public databases. The Siegel clinical evidence base at runDate consists of five FIH patients with 30-day data plus 15 EFS patients with 30-day data — aggregate n=20 at short follow-up. The 1,025-patient STAR pivotal trial is the definitive gate, and its primary completion was originally estimated at December 2025, but enrollment only began in April 2026, implying the original timeline was aspirational. Long-term PVL, structural valve deterioration, and durability data against the 10–15 year horizon relevant to younger low-risk TAVR patients are not yet available. Technical risks include rhenium supply concentration (rhenium is primarily mined as a byproduct of molybdenum in Kazakhstan and Chile), in-house tissue processing quality, delivery system complication rates in real-world (non-expert) operators, and whether the GALILEO procedural platform holds necessary regulatory clearances. No publicly disclosed adverse event reports, recalls, or FDA enforcement actions were found for any MiRus product.[CE044, CE045, CE046, CE047, CE048, CE049]

5.7 Exhibits

6.1 Customer Segmentation and Buyer / User / Payer Architecture

MiRus serves two structurally distinct customer populations that differ in buyer identity, proof of adoption, payment mechanism, and risk profile. In the TAVR segment, the "customer" is a hospital structural heart program and its team of credentialed interventional cardiologists and cardiac surgeons. Currently no commercial TAVR transaction exists anywhere in the world: the Siegel device is an investigational device exempt (IDE) product, and the only authorized end-users are clinical investigators enrolled in the IDE-approved EFS and STAR pivotal trial. Investigational device use is sponsored by MiRus, reimbursed under CMS Coverage with Evidence Development (CED) rules, and does not involve hospital procurement, formulary review, or supply-chain contracts. CMS approved the STAR trial under CED on March 27, 2026, and the EFS was approved March 28, 2025. The MiRus TAVR "customer" today is therefore a named clinical investigator at a named trial site — a clinical partner, not a paying commercial account. In the orthopedic and spine segment, the buyer is a hospital, ambulatory surgery center (ASC), or private surgery practice that purchases implant systems through MiRus's distributor network. End users are spine and orthopedic surgeons. The payer is typically a private insurer or Medicare/Medicaid, with procedure reimbursement flowing to the facility. The EUROPA® PCF system received a CMS New Technology Add-on Payment (NTAP) effective FY2026 (announced August 2025), providing an incremental per-case add-on payment for hospitals that adopt the product — a meaningful adoption incentive for the PCF, though NTAP is typically limited to two to three years. No revenue figures, customer counts, account names, or contract structures for the orthopedic/spine business have been publicly disclosed. The company's distributor page collects inquiries but does not name existing partners.[CU001, CU002, CU003, CU004, CU005, CU006]

6.2 TAVR Clinical Engagement — Sites, Investigators, and Proof Level

The clearest and most granular evidence of MiRus "customer" engagement sits in its TAVR trial program. For the U.S. early feasibility study (EFS, NCT06680427), MiRus enrolled 15 patients at five U.S. centers (March–late 2025). Only two of these five sites are publicly confirmed by name through press releases and independent trade coverage: Piedmont Heart Institute in Atlanta and Cedars-Sinai Smidt Heart Institute in Los Angeles. Dr. Pradeep K. Yadav, Director of Structural Interventions at Piedmont Heart Institute, performed the first EFS cases and presented 30-day results at New York Valves in June 2025 alongside Dr. Raj Makkar (chief of interventional cardiology, Cedars-Sinai Smidt Heart Institute). At 30 days, zero deaths, strokes, rehospitalizations, vascular complications, paravalvular leak, or permanent pacemaker implantations were recorded across all 15 patients; mean gradient was 6.3 mmHg and mean valve area 2.8 cm². These outcomes were presented in podium sessions, constituting physician-level endorsement of the device from two named, high-reputation centers. For the pivotal STAR trial (NCT07278310), MiRus enrolled and treated its first patients on April 8, 2026 at Piedmont Heart Institute. The ClinicalTrials.gov record as of June 2026 lists only Piedmont Heart Institute as an active recruiting site; additional sites have not yet appeared in the registry even though the trial design calls for enrollment at multiple U.S. centers. The trial chairpersons — Martin Leon, MD (Columbia University Medical Center) and Vinod Thourani, MD (Piedmont Heart Institute) — and national PIs Pradeep Yadav, Raj Makkar, Samir Kapadia, and Philippe Genereux are publicly named. Their institutional affiliations represent the expected geographic spread of STAR trial sites (East Coast academic centers, Atlanta, Los Angeles, Cleveland Clinic, Atlantic Health), though the registry has not yet published a full site list. The first-in-human procedures were performed in June 2024 at Instituto Nacional del Torax in Santiago, Chile, in five patients with severe symptomatic aortic stenosis. Results at 30 days showed no mortality or stroke, no permanent pacemaker requirement, and a mean echo gradient of 6.7 mmHg. These investigators function as physician champions and adoption validators, not commercial customers. Their participation generates clinical evidence and professional-society visibility, but does not create contractual commercial relationships, generate revenue for MiRus, or prove market-level adoption.[CU009, CU010, CU011, CU012, CU013, CU014]

6.3 Orthopedic and Spine Commercial Customer Base

MiRus's orthopedic and spine products are commercially marketed through independent sales representatives and a distributor network. The company's distributor page invites prospective distribution partners to register but does not list existing distributor names or territories. No public-facing customer case study, hospital deployment announcement, surgeon testimonial, or purchasing agreement has been identified for any of the 24 FDA-cleared spine and orthopedic products. This is consistent with early-stage small-device company practice of relying on distributor-driven, surgeon-to-surgeon networks where deal flow is private and institutional contracts are rarely announced. The EUROPA® PCF system with NTAP designation (CMS FY2026) provides the best public signal of hospital-level adoption incentive: the NTAP creates a direct economic benefit for hospitals that implant the device during the NTAP window (FY2026, with potential extension subject to CMS renewal). This would be expected to ease hospital formulary approval and accelerate initial commercial accounts. However, no hospitals receiving NTAP payments for EUROPA® PCF are publicly disclosed. The GALILEO™ Spine Alignment Monitoring System creates potential workflow stickiness for hospital and ASC customers that adopt it alongside the EUROPA® instrumentation, since procedural-planning-tool integration increases switching costs. Similarly, the lifetime limited warranty on MoRe® rod fracture is a differentiated commercial message for spine programs with high deformity surgery volume. Neither product-level stickiness factor has been linked to any confirmed named customer in the public record. The practical diligence gap is significant: without named commercial accounts, revenue figures, utilization rates, or distributor identities, it is impossible to assess the commercial depth, durability, or concentration of the spine/ortho business. MiRus's 250%+ revenue growth claim (Atlanta Business Chronicle, 2022) is the only public growth signal for the company as a whole, but it is stale and does not isolate the spine/ortho segment.[CU021, CU022, CU023, CU024, CU025, CU026]

6.4 Retention, Repeat Use, and Customer Durability

No retention metrics — net revenue retention (NRR), gross retention, churn rate, contract length, renewal data, or cohort analysis — exist in the public record for either business segment. This is an expected reality for a private company with an undisclosed commercial orthopedic revenue base and an entirely investigational TAVR program, but it leaves all customer durability analysis speculative. For TAVR, the concept of "retention" as normally applied to commercial accounts does not yet apply: trial sites participate under IDE protocols administered by MiRus's CRO and clinical affairs team, not under commercial supply agreements. A clinical site that completes EFS enrollment is expected to transition to the STAR pivotal trial at MiRus's direction, which represents a form of sequential engagement but is driven by regulatory pipeline requirements, not customer loyalty. The more relevant durability question for TAVR is whether lead investigators will advocate for the device post-approval: the published endorsements from Yadav, Thourani, Makkar, Leon, Kapadia, and Genereux suggest strong physician-champion alignment, but commercial adoption depends on system economics, FDA approval timing, and a post-market registry structure. For orthopedic/spine, the most relevant durability proxy would be reorder rates — whether surgeons trained on EUROPA® or IO™ products continue to prefer them over titanium or CoCr alternatives. The lifetime limited warranty on rod fracture is a structural retention incentive (ongoing product support), and the GALILEO™ ecosystem adds procedural switching costs. However, no utilization or reorder data are available. The NTAP adds a two-to-three year window during which hospital economics favor EUROPA® PCF adoption, after which price competition normalizes. No CMS claims data or commercial contract data confirming sustained hospital use have been identified.[CU027, CU028, CU029, CU030, CU031]

6.5 Expansion Path and Concentration Risks

MiRus faces pronounced concentration risk across both segments. In TAVR, the publicly confirmed customer engagement is dominated by Piedmont Heart Institute: it is the site of the EFS first cases (March 2025), the STAR first enrollment (April 2026), and the home institution of both the STAR trial co-chair (Thourani) and a national PI (Yadav). The clinical leadership structure creates a hub-and-spoke pattern in which Piedmont serves as the anchor site, with Cedars-Sinai as the second confirmed node. Loss of physician-champion support from either Yadav or Thourani would materially delay the STAR trial's primary-site enrollment momentum. The STAR trial's expected expansion to approximately 20 or more U.S. sites will broaden the institutional engagement, but the rate of site activation is not publicly disclosed and the registry had not listed additional sites as of the June 2026 run date. Commercial TAVR expansion after a potential PMA (likely 2028–2029 at earliest given a 2026 enrollment start) would require institutional credentialing at several hundred sites (approximately 700 certified TAVR programs in the U.S. per STS/TVT Registry data) and would compete directly with Edwards and Medtronic for procedure room time, structural heart team training, and capital allocation. MiRus's 8 French sheath advantage and nickel-free status provide differentiated entry points, but commercial customer acquisition in structural heart is a multi-year, capital-intensive endeavor. For orthopedic/spine, concentration in the distributor network is entirely opaque. If a small number of distributors or regional reps drive the majority of revenue, departure of key distributors would be material. The lack of any named distribution partner limits independent evaluation of channel health. EUROPA® PCF's Breakthrough Device Designation and NTAP create a two-to-three year window for concentrated hospital adoption in the cervical space, but without a post-NTAP commercial strategy backed by visible accounts, long-term durability is unconfirmed. An important adverse context is that the precedent of major TAVR platforms failing after promising trial data exists: Boston Scientific's ACURATE Neo2 and ACURATE Prime platforms were withdrawn from the global market in late 2023 after failing to receive FDA approval, demonstrating that strong early feasibility and European commercial traction do not guarantee U.S. approval or commercial success. This risk is not specific to MiRus but is directly relevant to evaluating commercial customer runway contingent on STAR trial success and PMA.[CU032, CU033, CU034, CU035, CU036, CU037]

6.6 Exhibits

7.1 Regulatory and Clinical Trial Risk

The most severe risk to MiRus is regulatory: the Siegel TAVR system requires a Pre-Market Approval (PMA) from the FDA as a Class III device, and no TAVR has ever received PMA without a successful large-scale randomized controlled trial. The STAR pivotal trial (NCT07278310) targets 1,025 patients across approximately 20 U.S. centers; as of June 2026, only Piedmont Heart Institute is listed as an active recruiting site on ClinicalTrials.gov. The EFS enrolled 15 patients at five centers over approximately twelve months (March–late 2025); extrapolating that pace to 1,025 patients without multi-site parallelization implies a trial completion timeline well beyond 2030, and PMA review adds 12–18 months beyond data lock. FDA's 2020 guidance requires 30-day, 1-year, and 5-year follow-up endpoints for structural heart PMA submissions, creating a multi-year regulatory clock that cannot be accelerated without additional site activation. The FDA granted Breakthrough Device Designation to the Siegel TAVR for the nickel-allergic patient subpopulation — a meaningful regulatory benefit that provides enhanced FDA interaction and potentially faster review. However, Breakthrough Designation does not lower the clinical evidentiary bar: the STAR trial must still demonstrate non-inferiority or superiority to approved comparators (SAPIEN 3, Evolut FX) on a composite primary safety-and-efficacy endpoint. Boston Scientific's Acurate neo2 was a cautionary precedent: after receiving CE mark, European commercial sales, and positive early registry data, the ACURATE TAVR program was formally discontinued in 2023-2024 when the FDA-required IDE trial showed the device failed to meet the predetermined noninferiority margin against SAPIEN and Evolut — leading BSX to abandon the entire program. The risk that Siegel, despite favorable 15-patient EFS data, encounters durability, hemodynamic, or safety issues at trial scale is real and unquantifiable until the STAR primary endpoint is reached. CMS coverage adds a second regulatory dimension. The STAR trial received unconditional Coverage with Evidence Development (CED) approval on March 27, 2026, enabling Medicare reimbursement for trial procedures. CED approval is trial-scope coverage only — it does not pre-authorize commercial reimbursement. Post-PMA commercial launch requires a new CMS coverage determination (NCD or LCD), which can take 12–24 months and may be conditional on registering all commercial cases in the TVT Registry (as is currently required for all TAVR). If FDA approves only a narrow indication (e.g., symptomatic severe AS in nickel-allergic patients), the addressable commercial population shrinks materially, reducing commercial revenue projections and the expected value of BSX's option. For orthopedic and spine products, near-term regulatory risk is lower: the EUROPA PCF system holds 510(k) clearance and an NTAP from CMS (effective FY2026). The IO Expandable Wedge system holds 510(k) clearance (K232154, September 2023). However, NTAP is time-limited — CMS typically grants NTAP for two to three fiscal years, after which the add-on payment lapses and hospitals absorb the full cost within DRG reimbursement, potentially reducing adoption incentives. No regulatory investigations, warning letters, or 483 observations against MiRus have been identified in public sources.[CR001, CR002, CR003, CR004, CR005, CR006]

7.2 Boston Scientific Dependency and Partner Risk

The strategic relationship with Boston Scientific is simultaneously MiRus's greatest source of capital and its greatest concentration risk. BSX's $1.5B equity investment for a 34% stake values MiRus at approximately $4.4B post-money; the accompanying exclusive option to acquire the TAVR business for additional aggregate payments of $3B creates a financial structure in which MiRus's TAVR trajectory is entirely aligned with whether BSX chooses to exercise. Two structural risks flow from this arrangement. First, the option creates asymmetric governance: BSX holds the exclusive right to acquire MiRus TAVR on terms that include "certain milestones" not publicly disclosed. MiRus therefore faces a scenario in which its most valuable asset is contractually reserved for a single buyer, preventing competitive M&A processes or IPO paths for TAVR without BSX consent (pending the option agreement terms). If trial milestones are missed or clinical data disappoints, BSX may decline to exercise — leaving MiRus without a commercialization partner for TAVR at the point of maximum capital need (pre-PMA, mid-trial). BSX declined to exercise comparable options on its own ACURATE platform after years of investment, demonstrating that large-cap medtech companies will abandon TAVR programs even when development capital has been sunk. Second, BSX's track record in TAVR is adverse: it discontinued the Lotus valve in 2016 following mechanical complications and delivery system design challenges, then terminated the ACURATE neo2 and ACURATE Prime programs globally in 2023–2024 after the IDE trial failed noninferiority. As of 2026, BSX has no approved TAVR product of its own and is relying on MiRus to fill that gap. This dependency creates aligned incentives for trial acceleration but also concentration risk: BSX's TAVR strategy is a single-company bet, and any deterioration in BSX's cardiac or structural heart business priorities (strategic pivot, acquisition, capital reallocation) could reduce support for MiRus. BSX reported Q4 2025 cardiovascular segment growth of 16.1% organically, indicating healthy underlying business fundamentals that support continued investment. However, BSX carries long-term debt of approximately $13–14B (per Q4 2025 earnings), meaning additional capital commitments — including the $3B option payment — are contingent on the company's broader capital allocation decisions. A deterioration in BSX credit markets or a large competing acquisition could reduce the probability of option exercise.[CR011, CR012, CR013, CR014, CR015, CR016]

7.3 Manufacturing, Supply Chain, and Material Risk

MiRus's competitive differentiation in both TAVR (Siegel) and orthopedics (EUROPA, RIGEL, IO systems) is built on the proprietary Molybdenum-Rhenium (MoRe) alloy. This differentiation creates a double-edged material risk: the same properties that make MoRe superior (rhenium content providing radiopacity, nickel-free biocompatibility, strength, and fatigue resistance) also create supply chain vulnerability, because rhenium is among the rarest and most geographically concentrated critical minerals on Earth. According to the U.S. Geological Survey Mineral Commodity Summaries 2025, U.S. apparent consumption of rhenium was approximately 27,000 kg in 2024, with net import reliance at 65%. Primary U.S. production (~9,500 kg) is a byproduct of molybdenum concentrate roasting at porphyry copper mines in Arizona and Montana. Ammonium perrhenate imports — the form used in alloy production — came primarily from Kazakhstan (26%), Canada (24%), and Poland (15%), with 35% from other sources. Geopolitical disruption in Kazakhstan (a major rhenium exporter), Chilean supply constraints (rhenium metal powder), or export controls on strategic materials could directly impact MiRus's ability to manufacture the MoRe alloy at scale. Rhenium prices are volatile and have risen substantially: the average price of 99.99% pure rhenium metal pellets was $1,370/kg in 2024, up from $1,030/kg in 2020 (per USGS MCS 2025), representing a ~33% increase over four years. A 180-degree reversal or further spike — which occurred during the 2007–2009 aerospace-demand cycle — could materially increase the cost of goods for all MiRus MoRe-based implants simultaneously. No public information exists on MiRus's rhenium sourcing agreements, supplier identities, inventory buffer, or contractual cost protections. The 2023 PubMed study on MoRe ion release characterization (Spine J. 2023) confirms the alloy's biocompatibility in physiologic environments but does not address manufacturing scalability or supply-chain redundancy. MiRus has not disclosed its manufacturing facility locations, quality management system certifications (ISO 13485, FDA QSR 21 CFR Part 820), or capacity constraints for scaling TAVR valve production to clinical and eventually commercial volumes.[CR018, CR019, CR020, CR021, CR022, CR023]

7.4 Physician/Site Concentration and Competitive Risk

MiRus's clinical and commercial TAVR prospects are highly concentrated in a small number of physician-champions. The STAR trial chair is Martin B. Leon, MD (Columbia University) and Co-Chair is Vinod H. Thourani, MD (Piedmont Heart Institute). The national Principal Investigators are Pradeep K. Yadav, MD (Piedmont; also MiRus founder's son and lead EFS operator), Raj Makkar, MD (Cedars-Sinai), Samir Kapadia, MD (Cleveland Clinic), and Philippe Genereux, MD (Atlantic Health System). This concentration in six named physicians at five institutions represents the entirety of publicly confirmed clinical advocacy for the Siegel device. Departure, incapacity, or disengagement of any of these investigators — particularly Dr. Yadav and Dr. Thourani at Piedmont, the sole active STAR site — would directly impair trial enrollment velocity. The investigator-PI relationship is also complicated by the fact that Jay S. Yadav, MD (MiRus founder and CEO) is the father of Pradeep Yadav, creating a potential conflict-of-interest disclosure risk that adverse observers will flag. Competitive risk intensifies as the STAR trial progresses. Edwards Lifesciences controls approximately 55–65% of the U.S. TAVR market with the SAPIEN 3 Ultra platform, supported by extensive TVT Registry outcomes data, device iterations (SAPIEN 3 Ultra RESILIA), and established IDN/GPO contracting. Medtronic's Evolut FX TAVR system has published 2-year randomized data (Evolut Low Risk RCT) showing significantly less bioprosthetic valve dysfunction (5x less prosthetic valve thrombosis, 9x less haemodynamic structural valve dysfunction than SAPIEN). These durability data advantages may become a competitive hurdle for the Siegel if the STAR 5-year data are not collected before commercial launch. Anteris Technologies received FDA IDE approval for its PARADIGM pivotal trial (DurAVR balloon-expandable TAVR with biomimetic leaflets) in November 2025, creating a third next-generation platform that will compete for clinical trial sites, investigators, and eventually market share with similar timing to MiRus. The competitive pressure on commercial launch timing is significant: if Edwards or Medtronic launch next-generation valves (RESILIA, Evolut FX Pro) with multi-year outcomes data before MiRus completes STAR, the clinical differentiation of the Siegel 8 Fr sheath and nickel-free design may be insufficient to displace entrenched incumbents in academic structural heart programs, particularly if Siegel lacks 2-year STAR data at launch.[CR024, CR025, CR026, CR027, CR028, CR029]

7.5 Financial Opacity, Execution Risk, and Thesis-Break Triggers

MiRus operates as a private company with no publicly disclosed financial statements. Revenue, gross margin, operating expenses, cash burn, or capital adequacy for either the TAVR or orthopedic/spine businesses are unknown. The implied post-money valuation from BSX's $1.5B for 34% equals approximately $4.4B — a figure that requires either substantial orthopedic revenue generation or a high probability of TAVR option exercise to be justified on a fundamental basis. Without disclosed financials, investors cannot independently assess the capital adequacy needed to complete STAR (typically $80–200M for a 1,025-patient Class III device RCT inclusive of site activation, coordination, adjudication, and regulatory submission costs), nor evaluate whether the $1.5B injection is sufficient runway to data lock without additional dilutive financing. The orthopedic/spine business provides a potential revenue bridge, but its scale is entirely undisclosed. No revenue figures, distributor identities, account concentration, or margin data have been published for EUROPA, RIGEL, IO Expandable, or Atlas Wedge products. The NTAP designation provides a time-limited commercial incentive for hospital adoption of the EUROPA PCF system, but NTAP programs typically expire in two to three fiscal years — a window that may elapse before the TAVR program reaches PMA decision. If orthopedic/spine revenue is insufficient to fund operations and the BSX option is not exercised, MiRus faces a capital gap at the most capital-intensive phase of its development. Execution risk is compounded by leadership concentration. Jay S. Yadav, MD/PhD, is the sole publicly named executive; no CFO, CMO, Chief Operating Officer, or Head of Regulatory Affairs has been publicly identified. Scaling a 1,025-patient RCT at 20+ sites while simultaneously operating a commercial orthopedic/spine business requires deep operational management bench strength. The absence of disclosed executive leadership makes it impossible to assess organizational resilience or succession planning. Thesis-break triggers — events that would structurally invalidate the investment thesis — include: (1) STAR trial primary endpoint failure or a major safety signal (Siegel-associated death, stroke, or permanent pacemaker rate exceeding comparator thresholds); (2) BSX electing not to exercise its TAVR option following a trial milestone miss; (3) FDA issuing a non-approvable letter or requiring additional studies post-STAR; (4) a rhenium supply disruption or regulatory action forcing product recall; and (5) a significant adverse event or FDA enforcement action against MiRus or its manufacturing sites. None of these are considered probable in isolation, but each is independently sufficient to materially impair or eliminate investment value.[CR031, CR032, CR033, CR034, CR035, CR036]

7.6 Exhibits

8.1 Investment thesis and anti-thesis

The MiRus investment thesis rests on three reinforcing pillars. First, the MoRe alloy platform creates a structurally differentiated material base—24 FDA 510(k)-cleared orthopedic devices and a nickel-free, corrosion-resistant structural-heart valve share the same proprietary alloy, giving MiRus a patent-moat argument that neither pure spine players nor TAVR incumbents can easily replicate. Second, the SIEGEL TAVR system addresses a real large-market need: the global TAVR market was $6.8 billion in 2024 and is growing at 6.6% CAGR toward approximately $9.9 billion by 2030, with Edwards controlling roughly 60–70% of U.S. volume; any durable new entrant capturing 3–5% share in a $10 billion market represents a $300–500 million annual revenue opportunity at prevailing TAVR ASPs of $25,000–$35,000. Third, Boston Scientific's $1.5 billion investment is not simply passive capital—it is a strategic validation signal from the world's second-largest cardiovascular medtech company, which has reviewed MiRus's proprietary data room and concluded that SIEGEL warrants a nine-figure bet plus a $3 billion option. That option structure is itself the most bullish element: if BSX exercises, the aggregate consideration implies a TAVR-business-only valuation above $3 billion post-approval, which is credible relative to Edwards's TAVR revenue multiple of approximately 10–12x annual TAVR revenue on its public market cap. The anti-thesis is equally serious. MiRus's $4.4 billion implied equity is entirely pre-approval: SIEGEL is in a 1,025-patient pivotal trial and is not approved for commercial sale in any country. The STAR trial's 1-year primary composite endpoint means the earliest plausible PMA submission is mid-2027 and the earliest approval is late-2027 to 2029 under an optimistic regulatory timeline. Boston Scientific's own track record is cautionary: it discontinued the ACURATE neo2 and ACURATE Prime TAVR platforms in Q2 2025 after spending approximately $200 million annually (≈$50 million per quarter globally) on a program that failed to gain FDA approval, demonstrating that even well-capitalized incumbents can suffer binary TAVR regulatory failures. Revenue, ARR, gross margin, customer count, and historical fundraising are all non-public, preventing independent underwriting. The $3 billion BSX option is not a committed obligation— BSX retains the right but not the obligation to exercise—and if STAR misses its endpoint, the option lapses and MiRus would face a recapitalization event for the TAVR program at a likely substantial discount to the current implied valuation. The orthopedic commercial business provides a partial floor but, at peer multiples, is unlikely to support anywhere near a $4.4 billion standalone valuation without TAVR upside.[CV001, CV002, CV003, CV004, CV005, CV006]

8.2 Valuation context and comparable set

The $4.4 billion implied equity is derived from arithmetic: $1.5 billion divided by approximately 34% equals a post-money equity of approximately $4.4 billion. This is not an independently audited figure and the stated "approximately 34%" introduces a range of roughly $4.2–4.65 billion. Boston Scientific's FY2025 total revenue was $20.07 billion growing at 19.9% year-over-year, and the cardiovascular segment grew 18.2% in Q4 2025. The strategic imperative behind the investment—re-entering TAVR after discontinuing ACURATE—is therefore grounded in a segment that is one of BSX's fastest-growing. For comparable-set analysis, four reference frames are appropriate for a clinical-stage TAVR / commercial spine hybrid. First, public cardiovascular medtech companies: Edwards Lifesciences reported FY2025 Q4 TAVR sales of $1.16 billion (annualizing to approximately $4.5 billion), and its SEC-registered 10-K for FY2025 was filed February 25, 2026; Medtronic's cardiovascular-focused operations appear in its SEC-registered annual filings; and Boston Scientific's 2025 10-K was filed February 17, 2026 at EDGAR. These companies trade at EV/TAVR-revenue multiples implying that high-growth structural heart franchises command premium valuations—Edwards alone represents the strongest reference. Second, strategic M&A precedents: J&J's acquisition of Abiomed in 2023 for approximately $16.6 billion valued a cardiac-support device company at a substantial premium to trailing revenue, illustrating that strategics will pay for option value in commercial cardiac devices. Third, comparable spine companies: Stryker's SEC-registered 10-K for FY2025 filed February 11, 2026 shows that premium spine businesses trade at 4–6x annual revenue—this sets a partial floor for the orthopedic segment. Fourth, clinical-stage milestone logic: at $3 billion BSX option value for the TAVR business post-milestone, the implied pre-milestone present value depends on the probability-weighted STAR outcome, estimated by public evidence at 60–80% (supported by zero 30-day major adverse events in 15 EFS patients, but not by pivotal randomized data). A pure financial investor underwriting at the $4.4 billion post-money level faces a challenging return profile: even in the bull case, the BSX option exercise reallocates TAVR proceeds to MiRus as a company-level event (not directly to co-investors unless cap table preferences allow), and entry at $4.4 billion post-money requires TAVR success plus meaningful orthopedic growth to clear a 2–3x return over a 5–7 year horizon. The valuation stance is stretched for financial investors and fair-to-attractive for BSX as the strategic buyer with already-established exercise rights.[CV001, CV002, CV005, CV006, CV007, CV010]

8.3 Scenario analysis — bull, base, and bear

Three scenarios capture the material range of outcomes. In the bull case, the STAR trial meets its non-inferiority primary endpoint on time (30-day readout of 1-year data by late 2027), FDA grants PMA approval in 2028–2029, Boston Scientific exercises the $3 billion TAVR option shortly after PMA, and the orthopedic business has grown to $300–500 million annual revenue supported by CMS NTAP and premium MoRe alloy differentiation. Total MiRus equity value at BSX option exercise represents a substantial multiple on the $4.4 billion post-money, creating strong returns for co-investors who entered at or near the BSX round price. In the base case, STAR succeeds but regulatory review is extended by 6–18 months beyond the optimistic timeline; BSX exercises the option but at slightly modified terms reflecting milestone renegotiation; and the orthopedic business continues growing but at single-digit rates. MiRus realizes its value through the BSX option exercise, with total outcomes in the $3.5–5.0 billion TAVR + orthopedic range depending on final exercise terms. Co-investors at the $4.4 billion post-money achieve modest but positive returns. In the bear case, STAR either fails its primary endpoint or is materially delayed beyond 2030, BSX does not exercise the option, and MiRus faces a recapitalization of the TAVR program. The orthopedic business provides a floor: 24 cleared products, CMS NTAP support, and a functioning distributor channel support a real commercial operation, but at undisclosed revenue scale and without TAVR optionality, the standalone orthopedic business at peer spine multiples (4–6x revenue) is estimated at $800 million to $3 billion depending on revenue scale, well below the $4.4 billion post-money. Co-investors at the BSX round price would face a loss in the bear case. This binary structure is the defining risk of the current valuation.[CV028, CV031, CV032, CV033, CV034, CV035]

8.4 Exit readiness and final diligence asks

MiRus's primary exit path is the BSX option exercise: a structured, pre-negotiated route to a strategic acquisition of the TAVR business for $3 billion contingent on clinical and regulatory milestones. This is an unusually well-defined exit for a private clinical-stage company and reduces the need for a traditional IPO or auction process for the structural heart segment. The orthopedic business could be retained by MiRus post-TAVR-option-exercise or separately monetized via sale to a spine strategic (J&J DePuy Synthes, Stryker, Zimmer Biomet). A secondary IPO of the combined entity is also possible if BSX does not exercise and the company achieves sufficient scale in orthopedics. Exit readiness for the TAVR track is therefore entirely milestone-gated: STAR primary endpoint readout, FDA PMA review, and CMS coverage determination are the three sequential gates that must pass before the option exercise becomes available. The orthopedic business is already commercially active and could be exit-ready independent of TAVR, but at undisclosed revenue scale, any strategic sale price is opaque to outside investors. Final diligence asks to underwrite this investment are substantial: private financial statements to establish orthopedic revenue, gross margin, and burn rate; STAR enrollment velocity data (sites activated, patients enrolled per month vs. plan); cap table showing pre-BSX dilution history, preference stack, and co-investor identity; rhenium supply agreements and COGS trajectory; BSX option milestone definitions verbatim; and CMS NTAP status and expiry for EUROPA PCF. These gaps represent material underwriting blockers that cannot be resolved from public evidence alone.[CV036, CV037, CV038, CV039, CV040, CV046]

8.5 Exhibits